Molecular evaluation of antibiotic susceptibility of Tropheryma whipplei in axenic medium
Open Access
- 1 February 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 55 (2) , 178-181
- https://doi.org/10.1093/jac/dkh524
Abstract
Objectives and methods: Whipple's disease is a rare multisystem chronic infection, involving the intestinal tract as well as various other organs. Tropheryma whipplei is a slow-growing facultative intracellular bacterium that remains poorly understood. In vitro antibiotic susceptibility testing has previously been assessed in cells using a real-time quantitative PCR assay. In this study, we have evaluated the antibiotic susceptibility of three strains of T. whipplei grown in axenic medium using the same assay. Results: The active compounds in axenic medium were doxycycline, macrolide compounds, penicillin G, streptomycin, rifampicin, chloramphenicol, thiamphenicol, teicoplanin, vancomycin, amoxicillin, gentamicin, aztreonam, levofloxacin and ceftriaxone, with MICs in the range 0.06–1 mg/L. Cefalothin was less active, with MICs in the range 2–4 mg/L. We found that co-trimoxazole was active with MICs in the range 0.5–1 mg/L, and sulfamethoxazole alone was active with MICs in the range 0.5–1 mg/L. MICs of trimethoprim varied from 64–128 mg/L. Conclusions: Co-trimoxazole was effective in vitro, but this activity was due to sulfamethoxazole alone. These results were in accordance with the fact that T. whipplei does not contain the encoding gene for dihydrofolate reductase, the target for trimethoprim.Keywords
This publication has 18 references indexed in Scilit:
- Antibiotic Susceptibility of Tropheryma whipplei in MRC5 CellsAntimicrobial Agents and Chemotherapy, 2004
- Genome-based design of a cell-free culture medium for Tropheryma whippleiThe Lancet, 2003
- Culture of Tropheryma whipplei from Human Samples: a 3-Year Experience (1999 to 2002)Journal of Clinical Microbiology, 2003
- Whipple's disease, genomics, and drug therapyThe Lancet, 2003
- Molecular Evaluation of Antibiotic Susceptibility: Tropheryma whipplei ParadigmAntimicrobial Agents and Chemotherapy, 2003
- Sequencing and analysis of the genome of the Whipple's disease bacterium Tropheryma whippleiThe Lancet, 2003
- Survival ofTropheryma whipplei, the Agent of Whipple's Disease, Requires Phagosome AcidificationInfection and Immunity, 2002
- Whipple's DiseaseClinical and Diagnostic Laboratory Immunology, 2001
- Cultivation of the Bacillus of Whipple's DiseaseNew England Journal of Medicine, 2000
- Whipple's Disease: Clinical, Biochemical, and Histopathologic Features and Assessment of Treatment in 29 PatientsMayo Clinic Proceedings, 1988